more

Moderna (MRNA)

(Delayed Data from NSDQ)

$68.28 USD

-1.40 (-2.01%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

J&J to Begin Human Study on Coronavirus Vaccine in July

by Zacks Equity Research Published on June 11,2020

J&J's (JNJ) goal is to supply more than 1 billion doses of the vaccine globally if it proves to be safe and effective.

pharmaceuticals

Fed Sparks Economic Concerns: Winning Investment Strategies

by Sanghamitra Saha Published on June 11,2020

The Fed now expects the U.S. unemployment rate to hit 9.3% this year and sees American GDP falling by 6.5% in 2020.

Drugmakers Target Coronavirus Vaccine in 2020: 4 Stocks in Focus

by Ritujay Ghosh Published on June 08,2020

Several drugmakers have started ramping up production, anticipating huge demand if the candidates prove successful.

Moderna (MRNA) Up 9.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research Published on June 06,2020

Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MRNANegative Net Change

Novavax Clinches $60M Defense Contract for Coronavirus Vaccine

by Zacks Equity Research Published on June 05,2020

Novavax (NVAX) secures a $60-million pact from the US Department of Defense to manufacture its COVID-19 vaccine candidate, NVX-CoV2373.

biotechs

AstraZeneca to Ensure Equal Access to Coronavirus Vaccine

by Zacks Equity Research Published on June 05,2020

AstraZeneca (AZN) signs three new supply deals to ensure broad and equitable global access to its COVID-19 vaccine following its successful development.

pharmaceuticals

Trump Picks 5 Coronavirus Vaccine Candidates Per NYT Report

by Kinjel Shah Published on June 04,2020

The candidates belong to five companies, Moderna, AstraZeneca, J&J, Merck and Pfizer.

AstraZeneca Inks Deal to Develop RMP Inhibitors for Cancer

by Zacks Equity Research Published on June 04,2020

AstraZeneca (AZN) signs an oncology agreement with Accent Therapeutics to develop novel therapies targeting RNA-modifying proteins for treating cancer.

pharmaceuticals

Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates

by Kinjel Shah Published on June 02,2020

Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.

5 Top Stocks Up 100%+ in May With More Room to Run

by Tirthankar Chakraborty Published on June 01,2020

Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."

Glaxo Plans to Make 1B Doses of Coronavirus Vaccine Adjuvant

by Zacks Equity Research Published on May 29,2020

Glaxo (GSK) set to enhance its manufacturing capacity to make 1 billion doses of its pandemic vaccine adjuvant, which can be used to improve efficacy and scale up of multiple COVID-19 vaccines.

pharmaceuticals

5 Reasons to Bet on Growth ETFs

by Sanghamitra Saha Published on May 28,2020

A few upbeat developments on the vaccine front, unprecedented economic help, reopening of economies and a few bullish economic datapoints should facilitate growth stocks ahead.

5 High Beta ETFs That Are in High Momentum

by Sanghamitra Saha Published on May 27,2020

Markets may rally ahead on hopes of coronavirus vaccines and recovering consumer sentiments. These high-beta ETFs that are in high momentum should gain ahead.

Biotech ETFs Soaring on COVID-19 Vaccine Progress

by Sweta Jaiswal, FRM Published on May 27,2020

Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.

The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology

by Zacks Equity Research Published on May 27,2020

The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology

medical

Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain

by Sweta Killa Published on May 27,2020

The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.